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Objectives: To explore contemporary antibiotic management of infections caused by carbapenem-30 
resistant Gram-negative bacteria (CRGNB) in hospitals. 31 
Methods: Cross-sectional, internet-based questionnaire survey. We contacted representatives of all 32 
hospitals with more than 800 acute-care hospital beds in France, Greece, Israel, Italy, Kosovo, 33 
Slovenia, Spain and selected hospitals in the United States. We asked respondents to describe the 34 
most common actual practice at their hospital regarding management of carbapenem-resistant 35 
Enterobacteriaceae,  Acinetobacter baumannii and Pseudomonas aeruginosa through close-ended 36 
questions. 37 
Results: Between January-June 2017, 115/141 of eligible hospitals participated (overall response rate 38 
81.6%, country-specific rates 66.7%-100%). Most were tertiary-care (99/114, 86.8%), university-39 
affiliated (110/115, 89.1%) hospitals and most representatives were infectious disease specialists 40 
(99/115, 86.1%). Combination therapy was prescribed in 114/115 (99.1%) hospitals at least 41 
occasionally. Respondents were more likely to consider combination therapy when treating 42 
bacteremia, pneumonia and central nervous system infections and for Enterobacteriaceae, P. 43 
aeruginosa and A. baumannii similarly. Combination of a polymyxin with a carbapenem was used in 44 
most cases, while combinations of a polymyxin with tigecycline, an aminoglycoside, fosfomycin or 45 
rifampicin were also common. Monotherapy was used for treatment of complicated urinary tract 46 
infections, usually with an aminoglycoside or a polymyxin. The intended goal of combination therapy 47 
was to improve effectiveness of the treatment and to prevent development of resistance. In general, 48 
respondents shared the misconception that combination therapy is supported by strong scientific 49 
evidence. 50 
Conclusions: Combination therapy was the preferred treatment strategy for infections caused by 51 
CRGNB among hospital representatives, even though high-quality evidence for carbapenem-based 52 
















Treatment of infections caused by carbapenem-resistant Gram-negative bacilli (CRGNB) represents a 55 
difficult challenge for physicians because of the paucity of antibiotics active against these bacteria 56 
and  potential inferior efficacy of the old drugs [1]. Mortality rates are high and despite increasing 57 
incidence of these infections worldwide there is no consensus on the most appropriate treatment 58 
strategy due to lack of high-quality evidence from randomised controlled trials (RCTs) [1,2]. 59 
In vitro studies suggest synergistic interactions between several antibiotic combinations against 60 
CRGNBs. Combinations that have shown synergy include colistin and rifampicin [3-5], carbapenem 61 
and sulbactam [4], polymyxin and a carbapenem [6,7], tigecycline and colistin [8], carbapenem and  62 
an aminoglycoside [9] and double carbapenem combinations [10,11] among others. Interactions are 63 
dependent on bacteria species (Enterobacteriaceae, Pseudomonas aeruginosa, Acinetobacter 64 
baumannii), the inoculum and the mechanisms of resistance [7]. 65 
Following these in vitro data, observational studies in the last decade suggested that combination 66 
therapy with two or more agents was associated with better outcomes compared to monotherapy 67 
with an active antibiotic [12-15], at least in patients with a high risk of death [16]. Unlike the in vitro 68 
studies, the observational studies commonly do not address defined antibiotic combinations [13]. 69 
Evaluating effectiveness from these studies is difficult due to difficulties in avoiding selection bias, 70 
addressing confounding, assigning the treatment groups as well as poor adherence to the assigned 71 
regimen in clinical practice [17,18].  72 
The aim of our cross-sectional questionnaire survey was to explore how hospital infection specialists 73 
manage infections caused by CRGNB in selected European countries, Israel and selected hospitals in 74 
the United States of America (USA). We wished to record the most common antibiotic practices 75 















Materials and methods 77 
Survey design 78 
The study was a cross-sectional internet-based questionnaire survey on therapy for infections caused 79 
by CRGNB. The questionnaire was designed with closed-ended questions and distributed using the 80 
SurveyMonkey® platform [19]. We requested information on the specialty of the participant, hospital 81 
name and size and type of hospital. Questions on monotherapy, double combination and triple 82 
combination therapy of infections caused by different carbapenem-resistant bacteria followed [20]. 83 
Finally, the use of carbapenems, polymyxins and tigecycline was investigated (the full questionnaire 84 
is available in the Supplementary File). The questionnaire was developed by two primary 85 
investigators (LP, MP) and pre-tested by all authors for clarity and technical functionality.  86 
Our target population were infectious diseases (ID), clinical microbiology (CM) physicians or 87 
pharmacists treating patients, giving advice on antibiotic treatment or the professionals responsible 88 
for antimicrobial stewardship programme (ASP). We asked respondents to reply describing the most 89 
common actual practice at their hospital. Only one participant from a particular hospital  was 90 
included. In Europe and Israel we included all hospitals with more than 800 acute care hospital beds 91 
(medicine/surgery/obstetrics) in countries reporting a high prevalence of CRGNB: France, Greece, 92 
Israel, Italy, Kosovo, Slovenia and Spain. In the USA, we selected hospitals where at least 10 patients 93 
per year were treated with polymyxins, based on surveys performed by KK for clinical studies 94 
(Florida, Georgia, Illinois, Maryland, Michigan, New York, Pennsylvania, South Carolina).  95 
Survey administration 96 
One investigator per country provided the list of all eligible hospitals in the selected European 97 
countries, Israel and the USA. One senior specialist (starting with the head of the ID/CM service or 98 
pharmacist specialised in infectious diseases and antimicrobial stewardship) per hospital was sent an 99 















obtained we searched for another contact person. Participants were able to access the questionnaire 101 
multiple times to allow for possible changes and completion at later times.  102 
The survey was voluntary, with no incentives offered to participants (other than being listed as an 103 
investigator).  104 
Response rates 105 
The unit measured with regards to the survey responses was the hospital. Response rates were 106 
calculated as number of hospitals from which an answer was recorded/total number of participating 107 
hospitals, overall and per country. Information on hospital name and country was used to screen for 108 
duplicate entries, but all data were subsequently anonymised for the analyses. 109 
Statistical analysis 110 
Both completed and partially completed questionnaires were analysed using the number of 111 
















The survey was administered between January-June 2017. One hundred and fifteen out of 141 114 
invited hospitals participated in the study (overall response rate 81.6%, country-specific rates 66.7%-115 
100%) (Supplementary File, Table S1). The vast majority of respondents were ID specialists (99/115, 116 
86.1%). Most participating centers were tertiary care (99/114, 86.8%) and university affiliated 117 
hospitals (110/115, 89.1%) (Supplementary File, Table S2). 118 
Factors influencing antibiotic choice 119 
Almost half of the respondents (54/111, 48.6%) reported having no guidelines regarding the 120 
treatment of infections caused by CRGNB, with the remainder having local guidelines (19.8%), 121 
national guidelines (18.9%) or both (12.6%). Source of infection, severity of the disease and the 122 
pathogen minimum inhibitory concentration (MIC) for the antibiotic were most frequently regarded 123 
as very important factors when choosing the antibiotic regimen for the treatment of infections 124 
caused by CRGNB (Table 1). The type of isolated microorganism and 125 
pharmacokinetic/pharmacodynamic profile of the antibiotic were also considered as important, 126 
while a patient's immune status was a lesser determinant of treatment choice.  127 
Antibiotics used 128 
The polymyxin used in almost all participating hospitals was colistin, most frequently dosed twice 129 
daily following a 9 million international units (MIU) loading dose (Table 2). Therapeutic drug 130 
monitoring for polymyxins was routinely used in 5/112 (4.5%) hospitals and was available for specific 131 
indications (e.g. renal failure) in 13/112 (11.6%) hospitals. The use of aerosolised polymyxin was 132 
frequent for ventilator-associated pneumonia (86/112, 76.8%). In more than half of hospitals, 133 
tigecycline was used in higher doses than approved: 200 mg daily in 54.5% (60/110) and 150 mg daily 134 
in 6.4% (7/110) of the hospitals. When included in combination therapy, the most common 135 















commonly used (Table 3). When asked about a MIC threshold for carbapenem use for CRGNBs, most 137 
respondents considered using a carbapenem-containing combination when the carbapenem MIC was 138 
≤ 8 mg/L. 139 
Combination therapy 140 
Combination therapy was prescribed at least sometimes in 114/115 (99.1%) hospitals. Respondents 141 
were more likely to consider combination therapy when treating bacteremia, pneumonia and central 142 
nervous system infections and for Enterobactericeae, P. aeruginosa and A. baumannii similarly (Table 143 
4). When asked on what basis the decision to use combination rather than monotherapy was based 144 
on, 63/110 (57.3%) declared they relied on in vitro studies, 69.1% relied on observational studies, 145 
55.5% on RCTs, 68.2% on systematic reviews and 53.6% on personal experience. The intended goal of 146 
combination therapy was most commonly to improve effectiveness of the treatment (103/110, 147 
93.6%) or to prevent development of resistance (73.6%). Less commonly combination therapy was 148 
used to avoid toxicity through dose reduction (5.5%).  149 
Carbapenem-resistant Enterobacteriaceae 150 
Treatment strategies for infections caused by carbapenem-resistant Enterobacteriaceae (CRE) are 151 
presented in Table 5. The mechanisms of carbapenem resistance reported by respondents as most 152 
frequent in their practice were production of Klebsiella pneumoniae carbapenemase (KPC) (64%) and 153 
oxacillinase-48 (OXA-48) (47.4%) (Supplementary File, Table S3). Combination therapy was a common 154 
strategy for treatment of CRE. When monotherapy was considered, aminoglycosides (40/57, 70.2%) 155 
or ceftazidime/avibactam (20/57, 35.1%) were used for complicated urinary tract infections (cUTIs) 156 
and tigecycline was used especially for intraabdominal infections (IAIs) (20/57, 35.1%) and skin and 157 
soft tissue infections (SSTIs) (20/57, 35.1%). The most popular choices for double combination 158 
therapy were combinations of a polymyxin with a carbapenem (e.g. for treating bacteremia in 63.9% 159 
(67/105) of hospitals) followed by a polymyxin with tigecycline (e.g. for treating IAIs in 58.1% 160 















carbapenem or an aminogycoside were common and the combination of an aminoglycoside with 162 
fosfomycin (34/105, 32.4%) was often used for cUTIs. For triple combination therapy, a regimen 163 
containing a polymyxin, tigecycline and either a carbapenem (e.g. for treating bacteremia in 55.6% 164 
(40/72) of hospitals) or an aminogycoside (e.g. for treating bacteremia in 29.2% (21/72) of hospitals) 165 
was often used in participating hospitals. 166 
Extensively drug-resistant carbapenem-resistant P. aeruginosa 167 
Antibiotic choices for treatment of infections caused by extensively drug-resistant carbapenem-168 
resistant P.aeruginosa (XDR CRPa) are shown in Table 6. Monotherapy was used mostly for cUTIs and 169 
ceftolozane/tazobactam (41/66, 62.1%)  was the preferred option, followed by aminoglycosides 170 
(32/66, 48.5%) or polymyxins (23/66, 34.8%). When treating with combination, a polymyxin was 171 
usually used as a backbone with a carbapenem (e.g. for treating bacteremia in 54.7% (52/95) of 172 
hospitals), an aminoglycoside or fosfomycin added to it. For triple combination therapy a polymyxin 173 
and a carbapenem were usually combined with either fosfomycin or an aminoglycoside. 174 
Extensively drug-resistant carbapenem-resistant A. baumannii 175 
Treatment options for infections caused by extensively drug-resistant carbapenem-resistant A. 176 
baumannii (XDR CRAb) are presented in Table 7. Monotherapy was used in 46/96 (47.9%) hospitals 177 
and mainly for cUTI. Aminoglycosides (29/46, 63%) and polymyxins (30/46, 65.2%) were the main 178 
treatment for cUTI and polymyxins for various different infections. Most respondents used double 179 
combination therapy for infections caused by CRAb. Combinations of a polymyxin with a carbapenem 180 
(e.g. for treating bacteremia in 60% (48/80) of hospitals) were most frequently followed by a 181 
polymyxin combined with either tigecycline or rifampin. Triple combination therapy was as 182 
commonly used as monotherapy; a polymyxin plus tigecycline with a carbapenem or rifampicin were 183 
the preferred choices.  184 















Israel was the only country where monotherapy was the preferred choice of treatment for infections 186 
caused by CRGNB, in all other countries combination therapy, usually the association of two 187 
antibiotics was the standard of care. However, monotherapy for cUTI was also very common in 188 
Kosovo, Slovenia, Spain and the USA. There were no major differences in the selection of antibiotics 189 
most commonly used, but some distinctions between countries were noted. Ceftolozane/tazobactam 190 
was commonly used for treatment of cUTI and pneumonia caused by XDR CRPa in France, Italy, Spain 191 
and the USA, while ceftazidime/avibactam was used often for treatment of infections caused by CRE 192 
in the USA. Polymyxin B was used only in some hospitals in the USA, all other hospitals used colistin. 193 
These differences were dictated by availability, as ceftolozane/tazobactam, ceftazidime/avibactam, 194 
polymyxin B and intravenous fosfomycin were not available in all countries at the time of the survey. 195 
















The aim of our survey was to explore treatment regimens for infections caused by CRGNB used by 198 
hospital infection specialists in various countries. Our results show that source of infection, severity 199 
of the disease and the MIC for the antibiotic were the most important factors influencing the 200 
antibiotic choice. Double combination therapy was the preferred strategy for CRGNB infections,  201 
especially when treating bacteremia, pneumonia and central nervous system infections. Combination 202 
of a polymyxin with a carbapenem was used in most cases, while combinations of a polymyxin with 203 
tigecycline, an aminoglycoside, fosfomycin or rifampicin were also common. Monotherapy was 204 
mainly used for treatment of cUTIs, usually with an aminoglycoside or a polymyxin. 205 
Ceftazidime/avibactam, approved by the US Food and Drug Administration at the time of the survey 206 
but not yet by the European Medical Association, was often used for monotherapy of infections 207 
caused by CRE in USA, while ceftolozane/tazobactam was used for monotherapy of infections caused 208 
by CRPa in all countries except Israel. Among polymyxins, colistin was almost universally used, mostly 209 
dosed twice daily after the initial 9 MIU loading dose. In more than 10% of the hospitals a loading 210 
dose was not used. Participants felt comfortable adding a carbapenem when the MIC was ≤ 8 mg/L, 211 
and carbapenems were commonly administered in prolonged infusions. Tigecycline was generally 212 
used for treating IAIs and SSTIs, often in higher than approved doses.  213 
In general, respondents shared the misconception that combination therapy is supported by strong 214 
scietific evidence (i.e. randomised-controlled trials). In fact, there were three RCTs published at the 215 
time of the survey that tested only two interventions, only for A. baumannii – colistin-rifampicin vs. 216 
colistin [21,22] and colistin-fosfomycin vs. colistin [23]. There were no published RCTs on 217 
carbapenem-combination therapy for CRGNBs (two underway at the the time of the survey, 218 
NCT01732250, NCT01597973). Many participants relied on systematic reviews; systematic reviews of 219 















systematic review graded the quality of the evidence on combination therapy for CRGNBs as very low 221 
quality, data that should not be used in guideline development or to support a recommendation [18].  222 
Clinical studies do not always mirror the results of in vitro studies [24]. Exact bacterial inoculum and 223 
antibiotic doses can be easily simultaneously assessed on agar plates but this may not be replicated 224 
in a septic patient. Even if combination therapy were to be timed perfectly, drug peneration to the 225 
site of infection cannot be controlled. Despite many in vitro studies demonstrating synergistic 226 
interactions and prevention of resistant strain emergence for beta-lactam-aminoglycoside 227 
combination therapy against Gram-negative bacteria, clinical studies failed to prove clinical benefits 228 
and there is no clinical demonstration of less resistance with the combination [25-28]. Indeed, the 229 
only RCTs to date of combination therapy for CRGNBs did not demonstrate reduced mortality or 230 
clinical failure with combination [21-23]. 231 
Carbapenems, mainly meropenem, were the most common antibiotics added to polymyxins in 232 
combination therapy regimens. Carbapenems  are among antibiotics most commonly associated with 233 
Clostridium difficile diarrhoea [29]. An even graver consequence of carbapenem treatment is 234 
induction of carbapenem resistance and selection of carbapenem-resistant strains. Studies show that 235 
carbapenem use is one of the most important risk factors  for colonisation and infection with CRGNB 236 
[30]. With carbapenem use as one of the main drivers of carbapenem resistance its routine use as 237 
part of the combination therapy for CRGNB infections in the absence of good quality data remains 238 
questionable. 239 
The strength of this survey is a high response rate, giving an insight into everyday practices of 240 
infection specialists dealing with CRGNB infections in participating countries. We restricted inclusion 241 
to large hospitals in Europe, since these hospitals are more likely to care for patients with severe 242 
CRGNB infections. The main limitation is that we did not access actual antibiotic prescription data, 243 















treatment strategies. However, we made it clear in the online survey and in correspondence with 245 
respondents that the survey intended to reflect actual common practice at the participating hospital.  246 
In conclusion, combination therapy is the preferred treatment strategy for infections caused by 247 
CRGNB even though high-quality evidence (supporting or not supporting this approach) are lacking. 248 
The absence of good quality studies, guidelines and recommendations resulted in a myriad of 249 
combination antibiotic regimens recorded in the survey. In the era of ever-growing carbapenem 250 
resistance good quality studies, especially RCTs, are urgently needed to ascertain the most effective 251 
treatment strategies regarding CRGNB infections. Evidence-based ESCMID guidelines on the 252 
treatment of infections caused by multidrug-resistant Gram-negative bacilli are to be published in 253 
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Table 1. Importance of different factors when choosing an antibiotic for treating infections caused by carbapenem-resistant Gram-negative bacilli 429 
Factor 
 
n (%), N=110 
Not important Moderately 
important 
Very important 
Source of infection (e.g. pneumonia, urinary tract infection etc.) 1 (0.9) 15 (13.6) 94 (85.5) 
Severity of the disease 2 (1.8) 15 (13.6) 93 (84.5) 
Immune status of the patient 0 (0) 50 (45.5) 60 (54.5) 
Renal or hepatic impairment 2 (1.8) 53 (48.2) 55 (50) 
Type of isolated microorganism (e.g. K. pneumoniae, P. aeruginosa, etc.) 1 (0.9) 25 (22.7) 84 (76.4) 
Type of carbapenemase (e.g. KPC, NDM etc.) 14 (12.7) 38 (34.5) 58 (52.7) 
Minimum inhibitory concentration (MIC) for the antibiotic 2 (1.8) 17 (15.5) 91 (82.7) 
Pharmacokinetic/pharmacodynamic (PK/PD) profile of the antibiotic 1 (0.9) 24 (21.8) 85 (77.3) 
Toxicity profile of the antibiotic 4 (3.6) 53 (48.2) 53 (48.2) 
Interactions of the antibiotic with other drugs 15 (13.6) 56 (50.9) 39 (35.5) 
 















Table 2. Polymyxin use in participating centers 430 
Characteristic Number of hospitals 
Main polymyxin used 
   Colistin 
   Polymyxin B 





Use of a loading dose 99/111 (89.2%) 1 
Colistin schedule 2 
   Twice daily 




Therapeutic drug monitoring (TDM) 
   Routinely 
   In specific situations 
   Do not use 






Aerosolised polymyxin with systemic antibiotics 
for ventilator-associated pneumonia (VAP) 
86/112 (76.8%) 
 431 
1 9 million international units in 96 hospitals 432 















Table 3. Carbapenem-containing combination regimens for carbapenem-resistant Gram-negative 434 
bacilli 435 
Carbapenem used for combination therapy n (%), N=109 
Doripenem 2 (1.8) 
Imipenem 26 (23.9) 
Meropenem 100 (91.7) 
Ertapenem  7 (6.4) 
Double-carbapenem combination therapy (ertapenem combined with 
another carbapenem) 
26 (23.9) 
No carbapenem-containing combinations 8 (7.3) 
Carbapenem MIC at which its use is considered n (%), N=106 
MIC ≤ 4 mg/l 10 (9.4) 
MIC ≤ 8 mg/l 47 (44.3) 
MIC ≤ 16 mg/l 20 (18.9) 
MIC ≤ 32 mg/l 10 (9.4) 
Carbapenem use regardless of the MIC value  19 (17.9) 
Use of prolonged carbapenem infusion in combinations n (%), N=105 
Yes 76 (72.4) 
No 29 (27.6) 
 436 















Table 4. Indications for use of combination therapy 438 
Source of infection n (%), N=110 
Complicated urinary tract infections 41 (37.3) 
Pneumonia 92 (83.6) 
Intraabdominal infections 80 (72.7) 
Skin and soft tissue infections 42 (38.2) 
Central nervous system infections 96 (87.3) 
Bacteremia of any source 91 (82.7) 
Bacteria n (%), N=109 
Carbapenem-resistant Enterobacteriaceae  98 (89.9) 
Carbapemem-resistant XDR P. aeruginosa  93 (85.3) 
Carbapenem-resistant XDR A. baumannii 90 (82.5) 
 
XDR: extensively drug-resistant 















Table 5. Most frequent antibiotic regimens for targeted treatment for infections caused by 440 
carbapenem-resistant Enterobacteriaceae 1 441 
Total N=114 cUTI Pneumonia IAI SSTI CNSI Bacteremia 
Monotherapy (N=57, 50%) 
POL 20 (35.1) 18 (31.6) 10 (17.5) 12 (21.2) 7 (12.3) 17 (29.8) 
TIG 5 (8.8) 9 (15.8) 20 (35.1) 20 (35.1) 3 (5.3) 8 (14) 
AMG 40 (70.2) 6 (10.5) 8 (14) 7 (12.3) 3 (5.3) 14 (24.6) 
FOS 19 (33.3) 1 (1.8) 1 (1.8) 0 (0) 3 (5.3) 3 (5.3) 
CAZ/AVI 20 (35.1) 16 (28.1) 17 (29.8) 16 (28.1) 5 (8.8) 17 (29.8) 
Double combination therapy (N=105, 92.1%) 
POL + TIG 13 (10) 43 (41) 61 (58.1) 40 (38.1) 9 (8.6) 34 (32.4) 
POL + CARB 53 (50.5) 63 (60) 52 (49.5) 35 (33.3) 52 (49.5) 67 (63.9) 
TIG + CARB 6 (5.7) 24 (22.9) 40 (38.1) 26 (24.8) 9 (8.6) 21 (20) 
TIG + AMG 9 (8.6) 12 (11.4) 32 (30.5) 26 (24.8) 3 (2.9) 18 (17.1) 
AMG + FOS 34 (32.4) 8 (7.6) 8 (7.6) 8 (7.6) 7 (6.7) 18 (17.1) 
Triple combination therapy (N=72, 63.2%) 
POL + TIG + CARB 12 (16.7) 39 (54.2) 36 (50) 22 (30.6) 21 (29.2) 40 (55.6) 
POL + TIG + AMG 9 (12.5) 17 (23.6) 17 (23.6) 6 (8.3) 6 (8.3) 21 (29.2) 
POL + TIG + FOS 4 (5.6) 14 (19.4) 8 (11.1) 6 (8.3) 8 (11.1) 13 (18.1) 
POL + AMG + FOS 17 (23.6) 7 (9.7) 4 (5.6) 2 (2.8) 4 (5.6) 15 (20.8) 
DOUBLE CARB + POL 8 (11.1) 11 (15.3) 7 (9.7) 5 (6.9) 12 (16.7) 13 (18.1) 
cUTI: complicated urinary tract infection, IAI: intraabdominal infection, SSTI: skin and soft tissue 
infection, CNSI: central nervous system infection, POL: polymyxin, TIG: tigecycline, AMG: 
aminoglycoside, FOS: fosfomycin, CAZ/AVI: ceftazidime/avibactam, CARB: carbapenem 















regimens are presented in Supplementary File, Table S4. 















Table 6. Most frequent antibiotic regimens of targeted treatment of infections caused by extensively 443 
drug-resistant carbapenem-resistant P. aeruginosa 1 444 
Total N=110 cUTI Pneumonia IAI SSTI CNSI Bacteremia 
Monotherapy (N=66, 60%) 
POL 23 (34.8) 15 (22.7) 12 (18.2) 14 (21.2) 7 (10.6) 13 (19.7) 
AMG 32 (48.5) 4 (6.1) 6 (9.1) 5 (7.6) 1 (1.5) 8 (12.1) 
FOS 11 (16.7) 0 (0) 0 (0) 1 (1.5) 1 (1.5) 1 (1.5) 
TOL/TAZ 41 (62.1) 27 (40.9) 28 (42.4) 23 (34.8) 10 (15.2) 20 (30.3) 
Double combination therapy (N=95, 86.4%) 
POL + CARB 41 (43.2) 58 (61.1) 51 (53.7) 40 (42.1) 43 (45.2) 52 (54.7) 
POL + RIF 6 (6.3) 15 (15.8) 9 (9.5) 10 (10.5) 12 (12.6) 13 (13.7) 
POL + AMG 33 (34.7) 27 (28.4) 32 (33.7) 23 (24.2) 9 (9.5) 35 (36.8) 
POL + FOS 30 (31.6) 26 (27.4) 18 (18.9) 19 (20) 15 (15.8) 22 (23.2) 
AMG + FOS 30 (31.6) 12 (12.6) 11 (11.6) 12 (12.6) 7 (7.4) 16 (16.8) 
Triple combination therapy (N=48, 43.6%) 
POL + CARB + RIF 7 (14.6) 17 (35.4) 14 (29.2) 13 (27.1) 16 (33.3) 15 (31.3) 
POL + CARB + AMG 15 (31.3) 16 (33.3) 16 (33.3) 13 (27.1) 9 (18.8) 20 (41.7) 
POL + CARB + FOS 17 (35.4) 12 (25) 10 (20.8) 9 (18.8) 14 (29.2) 12 (25) 
POL + AMG + RIF 5 (10.4) 4 (8.3) 7 (14.6) 5 (10.4) 8 (16.7) 11 (22.9) 
POL + AMG + FOS 12 (25) 9 (18.8) 6 (12.5) 5 (10.4) 7 (14.6) 10 (20.8) 
cUTI: complicated urinary tract infection, IAI: intraabdominal infection, SSTI: skin and soft tissue 
infection, CNSI: central nervous system infection, POL: polymyxin, AMG: aminoglycoside, FOS: 
fosfomycin, TOL/TAZ: ceftolozane/tazobactam, CARB: carbapenem, RIF: rifampicin 
1 Respondents could choose more than one treatment regimen. Detailed data on all antibiotic 















Table 7. Most frequent antibiotic regimens for targeted treatment of infections caused by 445 
extensively drug-resistant carbapenem-resistant A. baumannii1 446 
Total N=96 cUTI Pneumonia IAI SSTI CNSI Bacteremia 
Monotherapy (N=46, 47.9%) 
POL 30 (65.2) 21 (45.7) 16 (34.8) 18 (39.1) 13 (28.3) 19 (41.3) 
TIG 4 (8.7) 5 (10.9) 14 (30.4) 16 (34.8) 1 (2.2) 3 (6.5) 
AMG 29 (63) 5 (10.9) 5 (10.9) 5 (10.9) 1 (2.2) 9 (19.6) 
Double combination therapy (N=80, 83.3%) 
POL + TIG 18 (22.5) 37 (46.3) 39 (48.8) 33 (41.3) 8 (10) 26 (32.5) 
POL + CARB 35 (43.8) 42 (52.5) 40 (50) 33 (41.3) 35 (43.8) 48 (60) 
POL + RIF 15 (18.8) 24 (30) 15 (18.8) 15 (18.8) 17 (21.3) 19 (23.8) 
POL + FOS 20 (25) 16 (20) 9 (11.3) 11 (13.8) 10 (12.5) 14 (17.5) 
TIG + CARB 4 (5) 14 (17.5) 19 (23.8) 14 (17.5) 7 (8.8) 13 (16.3) 
Triple combination therapy (N=43, 44.8%) 
POL + TIG + CARB 13 (30.2) 24 (55.8) 24 (55.8) 18 (41.9) 15 (34.9) 22 (51.2) 
POL + TIG + RIF 7 (16.3) 18 (41.9) 13 (30.2) 15 (34.9) 11 (25.6) 14 (32.6) 
POL + TIG + AMG 5 (11.6) 8 (18.6) 10 (23.2) 7 (16.3) 5 (11.6) 15 (34.9) 
POL + TIG + FOS 6 (14) 7 (16.3) 9 (20.9) 6 (14) 7 (16.3) 7 (16.3) 
TIG + RIF + AMG 5 (11.6) 5 (11.6) 7 (16.3) 7 (16.3) 2 (4.7) 9 (20.9) 
cUTI: complicated urinary tract infection, IAI: intraabdominal infection, SSTI: skin and soft tissue 
infection, CNSI: central nervous system infection, POL: polymyxin, TIG: tigecycline, AMG: 
aminoglycoside, CARB: carbapenem, RIF: rifampicin, FOS: fosfomycin 
1 Respondents could choose more than one treatment regimen. Detailed data on all antibiotic 
regimens are presented in Supplementary File, Table S6. 
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